

# HIV and Corrections

This is a PDF version of the following document:

Module 6: [Key Populations](#)

Lesson 5: [HIV and Corrections](#)

You can always find the most up-to-date version of this document at <https://www.hiv.uw.edu/go/key-populations/hiv-corrections/core-concept/all>.

---

## Overview of United States Correctional System

### Background

The United States correctional system consists of local and tribal jails, state prisons, federal prisons, military and immigration facilities, and community correctional facilities, which includes probation and parole programs.[1]

- **Jails:** Typically jails house persons charged with a crime who are awaiting trial or transfer, as well as persons convicted who have sentences of less than 1 or 2 years. Persons leaving jail are often supervised on probation for a defined period of time.
- **Prisons:** In contrast to jails, prisons house persons convicted of a felony serving longer sentences. Whether the offense committed involves federal law or state law determines placement in a federal or a state prison.
- **Parole:** The term parole refers to conditional release from prison prior to completing a sentence with the responsibility of completing the remainder of the sentence in the community. Upon leaving prison, many people continue to be monitored by the correctional system on parole.

At any point in time, about twice as many persons are incarcerated in prisons in the United States than in jails, but over the course of a year the number of individuals incarcerated in the jail system far exceeds those incarcerated in prisons ([Figure 1](#)); this difference over a year results from the low turnover rates in prisons (longer stays and infrequent releases) versus high turnover rates in jails (shorter stays and frequent releases).[2]

### Global Prison Statistics

In 2021, the United States had the highest prison population in the world and the total prison population in the United States was higher than any other country ([Figure 2](#)).[3,4]

### United States Prison Statistics

The total adult population in the correctional system in the United States, including local jails, state prisons, and federal prisons, increased significantly during the 1980s and 1990s (largely as a result of the crackdown on illegal drug use), peaked in 2008, and then leveled off for about a decade, and has decreased in recent years ([Figure 3](#)).[4,5,6,7] According to the Bureau of Justice Statistics, at the end of 2021 the United States had an estimated 1,767,200 adults incarcerated in correctional facilities, of which 91% were male.[4] From 2007 through 2021, incarceration rates were consistently higher in Black and Hispanic individuals than among

than White individuals.[\[4,7\]](#)

# Epidemiology and Prevention of HIV in Correctional Setting

## Prevalence of HIV in Prisons

In the United States, during the years 1991-2021 the annual number of persons with HIV in state or federal prisons ranged from a high of 25,976 in 1998 to a low of 11,810 in 2021 ([Figure 4](#)).[\[8,9,10,11\]](#) Since the state prison population is much larger than the federal prison population, it is not surprising the number of persons with HIV in state prisons (10,600) far outnumbers the number in federal prisons (1,216).[\[8\]](#) Epidemiologic surveys indicate the prevalence of HIV in 2021 was approximately 1.1% among incarcerated persons in correctional facilities, which is markedly higher than the 0.3 to 0.4% HIV prevalence in the general United States population.[\[2,8,12\]](#) In 2021, the prevalence of HIV among persons incarcerated in state prisons varies significantly by geographic region, with Mississippi, New York, Louisiana, and Florida having the highest prevalence (2.0% or greater).[\[8\]](#)

## Injection Drug Use and HIV in Prisons

The higher prevalence of HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) within correctional facilities can partially be explained by the high percentage of persons incarcerated with a history of injection drug use. Although injection drug use may directly result in transmission of HIV, it is also associated with sexual activity that can increase the risk of HIV acquisition.[\[13\]](#) Although the number of persons who have ever injected drugs is not routinely assessed in prison populations, a 2017 Bureau of Justice Special Report, which was based on data collected during 2007-2009, noted that 17% of persons in state prisons reported regularly using heroin/opiates prior to incarceration, with the highest rates (22%) among persons 45 to 54 years of age.[\[14\]](#) Unfortunately, few correctional facilities currently offer medication-assisted treatment for opioid addiction, and many incarcerated persons continue to use illicit drugs while incarcerated if they are able to access the drugs.[\[15,16,17\]](#) Available data suggest that for persons with HIV and a history of opioid dependence, receipt of opiate agonist therapy within an HIV clinic upon release from prison improves HIV treatment outcomes in the community.[\[18,19\]](#)

## Gender Differences in HIV Prevalence in Prisons

In the United States, the absolute number of men with HIV in state or federal prisons is consistently far greater than the number of women with HIV, which is not surprising given the prison population is predominantly male. In contrast, when analyzing the prevalence rate of persons with HIV in state or federal prison, the percentage of persons incarcerated who have HIV is similar among males and females. For example, in 2021, among persons incarcerated with HIV, 95% were male, but the percentage of women with HIV (0.9%) was similar to that in men (1.2%).[\[9\]](#) The Department of Justice does not provide HIV data in correctional facilities for transgender individuals.

## Racial Differences in HIV Prevalence in Prisons

In recent years, the Department of Justice has not provided HIV prevalence data in correctional facilities based on race.[\[9,11\]](#) The Department of Justice does report on AIDS-related deaths in prison based on race, and the death rates are higher among Black individuals than in White or Hispanic individuals.[\[11\]](#)

## Intra-Prison HIV Transmission

Although consensual sex, rape, tattooing, and injection drug use occur within the correctional setting, available data suggest that most persons with HIV who are incarcerated acquired HIV prior to entering prison or, for those with multiple incarcerations, between periods of incarceration.[\[13,20,21\]](#) A large meta-analysis estimated the incidence of transmission of viral infections within prisons and found rates of 0.08 per 100 person-years with HIV.[\[13\]](#) In a study conducted among incarcerated male individuals in a Georgia state prison system, intra-prison transmission of HIV was associated with male-male sex in prison, receipt of tattoos

while in prison, age older than 26 years, having served at least 5 years of the current sentence, Black race, and low body mass index upon entry to prison.[20]

## **Prevention of Intra-Prison Transmission of HIV, HCV, and HBV**

Many have called for a comprehensive strategy to help stop HIV transmission within the correctional system, through interventions such as voluntary counseling and testing, disease prevention education, and treatment for substance use disorders.[22] Other strategies include access to condoms, regulated tattoo parlors in prison, and facility-based needle exchange programs. All of these infection control strategies would also provide an opportunity to address prevention of infection with hepatitis C virus (HCV), which is important given that as many as 41% of incarcerated persons have chronic HCV.[16] The same meta-analysis noted above in the Georgia state prison system also reported an intra-prison HCV transmission rate of 0.75 per 100 person-years, which was significantly higher than the intra-prison HIV rate.[13] The transmission of HBV within prisons could be reduced by immunizing all HBV-non-immune incarcerated persons with hepatitis B vaccine.[13,16,23] The CDC recommends hepatitis B vaccination for all incarcerated persons who do not have immunity to or active infection with HBV.[23]

# HIV Testing in the Correctional Setting

## HIV Testing Practices in Correctional Facilities

In the United States, upon entry into jail or prison, it is estimated that approximately 22% of persons with HIV are unaware they have HIV.[24] Although the Centers for Disease Control and Prevention (CDC) recommended in 2006 that correctional facilities perform routine opt-out HIV testing, the HIV testing practices and policies in correctional settings continue to vary from state to state.[9,25,26] Data on state prison HIV intake testing practice for 2021 showed that 16 states performed mandatory HIV testing (tested all prisoners regardless of the need for consent) and 23 states provided opt-out HIV testing (offered the HIV test and the test was performed unless the prisoner declined); these practices have changed some from earlier years (Figure 5).[8,9] An opt-in HIV testing approach is when the prisoner requests the test or the test is offered and performed only if the prisoner consents to the test. The use of an opt-out HIV testing approach increases the number of persons tested for HIV when compared with the use of an opt-in HIV testing approach.[27,28] Jails, prisons, and community corrections are important settings in which to test individuals for HIV, especially given that many persons involved with the criminal justice system may be hard to reach with routine community-based testing and incarcerated populations have a higher HIV prevalence than the general population.[29,30,31]

## Studies of HIV Testing in Correctional Facilities

Studies have shown that HIV testing within the structured environment of corrections is effective and feasible; the cost-effectiveness of testing incarcerated populations varies with the prevalence of undiagnosed HIV among incarcerated individuals in any given testing area, but, overall, is on par with the cost of testing in the non-correctional setting.[29,32,33,34,35] One HIV testing project that included more than 33,000 incarcerated persons in four states (Florida, New York, Wisconsin, and Louisiana) identified 269 (0.8%) previously undiagnosed HIV, and 40% of them were among incarcerated persons whose only reported risk was heterosexual contact; this study underscores why HIV testing based only on reported risk factors will fail to identify a significant proportion of incarcerated persons with HIV.[35] A more recent CDC HIV corrections testing project conducted from 2009-2013 found 0.3-0.4% of incarcerated persons tested in a broad range of correctional facilities were newly diagnosed with HIV (Figure 6).[36] The CDC has released a comprehensive document to guide the implementation of opt-out HIV testing in the correctional setting.[37]

## **HIV Medical Care in Correctional Setting**

### **Access to Medical Care**

The landmark Supreme Court *Estelle v. Gamble* decision in 1976, which established that all incarcerated individuals have the right to adequate healthcare, provides the constitutional mandate for HIV care and access to treatment within the correctional setting.[38,39]

### **Linkage to HIV Medical Care and Referral to Partner Services**

Receiving a new diagnosis of HIV while in a jail or prison can be difficult; thus, appropriate counseling and linkage to care during incarceration are essential components to any correctional testing program, just as in noncorrectional settings.[40] The 2009 CDC document on HIV Testing Implementation Guidance for Correctional Settings provides specific recommendations on management of persons newly diagnosed in a correctional facility, including recommendations that address immediate clinical management issues and linkage to appropriate medical care during incarceration.[37] The immediate clinical management issues that should be addressed include HIV prevention counseling, referral for mental health treatment if needed, initial evaluation and staging of HIV, and referral for HIV treatment ([Table 1](#)).[37] The linkage to appropriate medical care during incarceration can be challenging since HIV specialists may not be available to provide medical services on-site at the correctional facility. Incarcerated persons with newly diagnosed HIV may require outside expert medical consultation.[36]

# Antiretroviral Therapy in the Correctional Setting

## Initiation and Continuation of Antiretroviral Therapy

Considering the high prevalence of HIV in the correctional settings, it is imperative that strategies and systems are in place to maximize initiation and uninterrupted administration of antiretroviral therapy within jails and prisons. Indeed, for some individuals, the structured environment of incarceration may lead to better adherence to antiretroviral treatment than with their adherence in a community setting, regardless of how the medications are dispensed.[15,41] Several studies evaluating the impact of directly observed antiretroviral therapy in prisons have found that directly observed antiretroviral therapy does not necessarily lead to better medication adherence than self-administration. Directly observed antiretroviral therapy is less convenient, decreases patient control, and may inadvertently jeopardize confidentiality.[15,42] In addition, directly observed antiretroviral therapy in the correctional setting does not empower incarcerated individuals to develop the habits of eventually taking antiretroviral medications on their own—skills they will need in the community. There is a wide range of practices and some correctional facilities utilize the “keep on person” approach where the incarcerated individual takes their own medication.[43]

## Barriers to Antiretroviral Therapy Success in Correctional Settings

Many of the barriers to successful antiretroviral therapy within prison are similar to those outside the correctional system. These include untreated mental illness, medication side effects, lack of trust in the medical provider or in the benefit of taking antiretroviral medications, and social isolation.[44,45] In Connecticut, psychiatric disorders were common in the cohort of incarcerated individuals with HIV, and 45.6% were taking either antidepressants or antipsychotic medications.[15] Incarcerated women with HIV have an even higher prevalence of psychiatric disorders than their male counterparts.[46] In the prison setting, unique barriers to antiretroviral adherence exist, such as frequent transfers between facilities or assignments within the facility that can interfere with continuity of care.[45] Some prison-specific barriers include unauthorized medication confiscation, medication theft, medication stock-outs, and inability to access medications during lockdowns.[40] Incarcerated persons may have concerns about confidentiality and/or lack trust in the prison health care system; these concerns may compromise adherence and deter individuals from acknowledging their HIV status and accessing HIV care.[40,45]

## Access to Antiretroviral Therapy in Correctional Settings

By law, antiretroviral therapy must be available to all incarcerated individuals who have HIV. The ability of correctional facilities to successfully provide antiretroviral treatment for incarcerated persons with HIV is variable.[31] One analysis, based on total antiretroviral sales in correctional facilities, found a substantial unmet need for HIV treatment in state and federal facilities, highlighting a major treatment gap.[47] Financial barriers also prevent timely initiation or continuation of antiretroviral therapy in correctional settings. Antiretroviral medications are expensive, and insurance no longer covers these medications in the correctional facility; annual budgets in small- to moderate-sized jails are often too small to support payment for antiretroviral medications for even a limited number of persons with HIV.[47] Jails and temporary detention settings pose the most challenges in terms of accessing antiretroviral therapy. Persons with HIV who have incarceration periods for fewer than 7 days have the highest risk of treatment interruption; this is likely due to the chaotic nature of the jail setting, with rapid turnover, unpredictable lengths of stay, and lack of communication with regular care providers.[48] Also, with short stays there may be inadequate time to collect a medical history, inquire about and verify current and previous medication regimens, or obtain the necessary antiretroviral medications before an individual is released.

## HIV Care Cascade and Outcomes in the Correctional Setting

The HIV care cascade model has been applied to the correctional system in order to identify disparities and improve performance at every stage along the HIV care continuum, from HIV diagnosis to linkage and retention in care to antiretroviral therapy and virologic suppression ([Figure 7](#)).[\[24\]](#) Fewer than 30% of persons with HIV in the United States who enter the correctional system do so with an undetectable HIV RNA level.[\[15,24\]](#) For some incarcerated persons with HIV, the correctional setting may be their first engagement in HIV care, and during incarceration, substantial gains may be made along all steps in the HIV care cascade, including increasing the percentages of persons taking antiretroviral therapy and achieving virologic suppression. In a retrospective review involving 882 prisoners with HIV in the Connecticut Department of Corrections system, virologic suppression (less than 400 copies/mL) improved from 29.8% at entry to 70.0% by release.[\[15\]](#) For many incarcerated persons with HIV, the greater ability to achieve viral suppression in prison is likely influenced by access to HIV care and mental health services, a structured daily routine, and decreased use of alcohol and illicit drugs.[\[15\]](#) Unfortunately, large declines in the HIV care cascade are seen after release from incarceration, often to levels even lower than before incarceration.[\[24,49\]](#)

### AIDS-Related Deaths Among Persons in State and Federal Prisons

As a result of improvements in antiretroviral therapies over time, the number of AIDS-related deaths in corrections has plummeted since the mid-1990s, similar to the trend in the general population.[\[11\]](#) Since 2010, fewer than 75 AIDS-related deaths per year have occurred among persons with HIV who were incarcerated in state prisons ([Figure 8](#)).[\[9,11\]](#) In addition, since 2010, fewer than 10 AIDS-related deaths per year have occurred among persons with HIV who were incarcerated in federal prisons.[\[11\]](#)



# Maintaining Confidentiality in the Correctional Setting

## Privacy and Confidentiality in Correctional Settings

Maintaining confidentiality in jails and prisons can be challenging, since the health information of prisoners is not always considered a protected entity. In the typical noninstitutional medical setting, confidentiality in the context of healthcare is a protected entity under the Health Insurance Portability and Accountability Act (HIPAA). In the correctional context, the relationship between the incarcerated person's privacy and institutional "right-to-know" remains contested, since correctional institutions are not always considered covered entities under HIPAA. Within a correctional facility, the health and safety considerations for an inmate may take priority over the right to confidentiality, but some have interpreted this to mean that all officers should know the HIV status of individuals who are incarcerated.[50] In this setting, however, the use of universal precautions should negate the need for correctional staff outside of health services to know the HIV status of any individual patient. The privacy of the incarcerated individual should be protected to the greatest extent possible, which typically means that medical interviews with the incarcerated person should be conducted out of earshot of correctional officers, and the disclosure of protected health information should be limited to situations that directly impact the health and safety of other incarcerated persons and/or correctional staff.[51]

## Disclosure of HIV Status

Because individuals with HIV in the correctional system often perceive that accessing HIV care may increase their risk of being subjected to violence due to stigma or homophobia, maintaining adequate privacy measures within the correctional system is of paramount importance.[40] In a small exploratory study of 42 men and transgender women with HIV who were recently released from correctional centers in Illinois, only about one-half of the men said they reported their HIV status at jail or prison entry, and some study participants only disclosed their HIV status to the correctional officers when their health deteriorated.[40] Fear of interpersonal violence, stigma, and lack of safety and privacy were cited as key reasons for HIV non-disclosure.

## Cohorting of Incarcerated Persons with HIV

Because of limited access to HIV specialists, some prison systems have attempted to cohort persons with HIV in one or two facilities that have the easiest access to the specialists they needed. Unfortunately, this practice limits incarcerated persons with HIV from transferring to facilities that may have unique work or school programs, and may result in persons with HIV being imprisoned far from visitors, thereby limiting or preventing visitations. In addition, this process is stigmatizing to the incarcerated person with HIV, and the cohorting process likely identifies them as a person with HIV. Further, efforts to cohort incarcerated persons with HIV also have in some cases led to adverse health outcomes, due to close proximity of multiple persons with immune suppression. In one instance, a single case of tuberculosis rapidly spread among the incarcerated persons with HIV in one facility, and ultimately 31 individuals developed tuberculosis.[52] In the past, some correctional administrators and officials thought placing all incarcerated persons with HIV together in special units—and in some cases identifying them by an armband or special clothing—would reduce HIV transmission to both staff and other incarcerated persons. This has never been shown to be true, and facilities in the United States now do not use this HIV cohorting stigmatizing practice.[53]

# Chronic Medical Conditions Among Incarcerated Persons with HIV

## Complexity of Care

Prevalence studies of incarcerated populations in the United States have found higher rates of multiple chronic medical conditions, including hypertension, cardiovascular disease, asthma, arthritis, and malignancies, when compared with the general population in the United States, even with adjustment for sociodemographic factors and alcohol consumption.[54,55,56] Incarcerated persons with HIV have high rates of HCV coinfection, more mental health problems, and lack of education:

- **HCV:** Various studies have determined that HCV prevalence among the general incarcerated population in the United States ranges from 15% to 40% depending on the region of the country.[16,57] Rates of HCV are considerably higher among those with HIV.[28,57] In a study of incarcerated individuals entering the Maryland Department of Corrections, HCV infection was five times more common among incarcerated persons with HIV compared with incarcerated persons without HIV (65% of incarcerated persons with HIV had HCV coinfection).[58] High rates of injection drug use in these study populations underlie this dual epidemic.
- **Mental Illness:** People with HIV have higher rates of mental illness compared with the general population and incarcerated populations also show a high prevalence of mental health disorders.[59,60] The Justice Department estimates that 50% of incarcerated individuals have a mental health disorder, and this percentage is likely to be even more prevalent among incarcerated persons with HIV.[61] The need to link incarcerated persons exiting the corrections setting to needed mental health services in the community is the basis of the Special Projects of National Significance (SPNS) initiative called Enhancing Linkages to Primary Care and Services in Jail Settings (EnhanceLink), which works to connect individuals with community counseling and support services.[62]
- **Lack of Education:** The lack of education is a pervasive and often overlooked issue among incarcerated populations. It is estimated that 3 out of 5 incarcerated persons have difficulty reading and writing, and 85% of juveniles who are incarcerated have difficulty reading. Lack of education has been linked to higher rates of crime and poverty; the lack of basic education also complicates the delivery of quality medical care since persons with low literacy may be less able to follow medical advice or even read their prescription labels.[63] Due to stigma and shame, many patients do not disclose their inability to read to their medical provider unless asked directly.

## Use of Telemedicine for HIV Care in Correctional Settings

Incarcerated persons with HIV often present complex management challenges to prison medical staff who lack HIV expertise. As noted earlier, other non-HIV-related chronic medical conditions may also complicate care. Treatment by experts in HIV medicine is strongly correlated with better medical outcomes, so one solution to the knowledge gap has been to introduce HIV subspecialty care to the prison setting through telemedicine.[64,65] Developing new models of prison healthcare, such as telemedicine, that can effectively deliver best-practice HIV medicine to incarcerated persons living with HIV, is crucial to ensuring the constitutionally protected right of incarcerated individuals to adequate healthcare.

# Transition from the Correctional Setting to the Community

## Importance of Transition Planning

The transition from a correctional facility to the community is a critical event for incarcerated persons with HIV. The CDC report on HIV Testing Implementation Guidance for Correctional Settings includes recommendations on linkage to appropriate medical care upon release from custody ([Table 2](#)).<sup>[37]</sup> Adequate discharge planning and linkage to community medical care upon release often fall short of practices recommended by the CDC, and only 30% of individuals are retained in HIV medical care after 6 months in the community.<sup>[24,28]</sup> Release from prison has been associated with increases in HIV RNA levels and decreased CD4 counts, which reflect some of the challenges with engaging in medical care and adhering to antiretroviral therapy while trying to reintegrate into society.<sup>[45,66]</sup> Programs that enhance linkage and entry into HIV care are crucial.<sup>[24,67]</sup> Multiple potential interventions can improve linkage to care, including HIV education during incarceration, careful discharge planning, securing stable housing, availability of transportation, employment opportunities, and care for substance use and mental health disorders.<sup>[24,68]</sup> Individuals taking antiretroviral therapy at the time of discharge should receive an adequate supply of antiretroviral medication as a bridge from jail or prison release to an appointment with a community provider. Community clinics and correctional systems need to work together to find ways to adequately meet the needs of this population upon re-entry into the community.

## HIV Transmission Risk After Release

After release from prison or jail into the general community, persons with HIV may engage in sex activities that may increase their risk of transmitting HIV to others, particularly with their pre-incarceration sex partners.<sup>[69,70]</sup> Several studies have shown that women have an increased risk of acquiring HIV when they have sex with a male partner with HIV who is released from prison.<sup>[71,72]</sup> Therefore, in this setting, it is important to utilize a range of HIV prevention strategies that include keeping released individuals engaged in medical care, assisting them in taking antiretroviral therapy, consistently achieving suppressed HIV RNA levels, identifying and treating sexually transmitted infections (since sexually transmitted infections can increase the risk of HIV transmission to partners), and facilitating the use of preexposure prophylaxis (PrEP) for community serodifferent partners.<sup>[68,69]</sup> Adherence counseling is particularly important. Moreover, some investigators have also demonstrated that incarceration disrupts primary intimate relationships, suggesting that use of prison-based programs to help prisoners and their partners maintain their relationship during incarceration may reduce the number of sexual contacts after release.<sup>[73]</sup>

## Community Corrections

Community corrections refers to adults on probation or parole.<sup>[74]</sup> At the end of 2021, among the total correctional population of 5,44,900 in the United States, approximately 3.7 million were in community corrections ([Figure 9](#)).<sup>[4]</sup> The demographics of community corrections closely mirror that of jail and prison settings, with disproportionate representation of poor, disadvantaged, and racial and ethnic minorities.<sup>[74]</sup> Inadequate data exist regarding HIV prevalence in community corrections, and HIV testing rates are low in this setting.<sup>[75]</sup> Nevertheless, the community corrections population represents an important target for HIV screening and prevention services. For persons with HIV, the community or parole officer can often play a key role in keeping an individual engaged in care. These officers are an underutilized resource, perhaps because of the public's misunderstanding of their role. The officers can help provide guidance, support, and program opportunities to persons in the community correctional system while helping them remain accountable for their imposed conditions as they transition back into the community. At times, obtaining a release of information from a patient to discuss their care with the community corrections officer or parole officer is an important step in coordinating medical care.

## Summary Points

- As of year-end 2021, the United States had approximately 1.8 million persons housed in correctional facilities, which exceeded that of all other countries.
- Among persons in correctional facilities in the United States, approximately 90% are male and incarceration rates are consistently higher in Black and Hispanic individuals than among White individuals.
- In the United States, the HIV prevalence among incarcerated individuals is 1.1%, which is more than three times higher than among the general population.
- Among all adults with HIV in prisons in the United States, approximately 95% are men and 5% women.
- In state prisons, HIV testing practices during prison intake vary and most states utilize mandatory or opt-out testing policies.
- Incarceration offers a structured environment to initiate and continue antiretroviral therapy.
- Barriers to successful antiretroviral therapy within the correctional setting include high rates of substance use and mental health disorders, lack of continuity of medical care, distrust of prison-based medical care, and concerns about confidentiality and safety.
- The transition from a correctional facility to the community is a critical event for persons with HIV. After release drop offs occur at every step of the HIV care cascade; linkage to HIV care and programs for reentry into HIV care are very important.
- Since individuals often engage in activities that may increase risk for HIV acquisition following release from the correctional setting, secondary prevention is a critical component of transitional care planning.
- High rates of HIV risk activity coupled with low rates of HIV testing make the community corrections population an important priority for HIV screening and prevention services.

## Citations

1. National Institute of Corrections. US Department of Justice. [\[National Institute of Corrections\]](#) -
2. Spaulding AC, Seals RM, Page MJ, Brzozowski AK, Rhodes W, Hammett TM. HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. PLoS One. 2009;4:e7558. [\[PubMed Abstract\]](#) -
3. World Prison Brief: Highest to Lowest—Prison Population Total. World Prison Brief, Institute for Criminal Policy Research. 2021 [\[World Prison Brief\]](#) -
4. Carson EA, Klucklow R. Correctional Populations in the United States, 2021 – Statistical Tables. Bureau of Justice Statistics: Office of Justice Programs, U.S. Department of Justice. February, 2023. [\[Bureau of Justice\]](#) -
5. Drucker E. Drug prohibition and public health: 25 years of evidence. Public Health Rep. 1999;114:14-29. [\[PubMed Abstract\]](#) -
6. Bureau of Justice Statistics, Annual Probation Survey, Annual Parole Survey, Annual Survey of Jails, Census of Jail Inmates, and National Prisoner Statistics Program, 1980-2016. April 26, 2018. [\[Bureau of Justice Statistics\]](#) -
7. Carson EA. Prisoners in 2018. Bureau of Justice Statistics: Office of Justice Programs, U.S. Department of Justice. April, 2020. [\[Bureau of Justice Statistics\]](#) -
8. Maruschak LM, Bronson J. HIV in Prisons, 2015—Statistical Tables. Bureau of Justice Statistics: Office of Justice Programs, U.S. Department of Justice. August 24, 2017. [\[Bureau of Justice\]](#) -
9. Maruschak LM, Bronson J. HIV in Prisons, 2021—Statistical Tables. Bureau of Justice Statistics: Office of Justice Programs, U.S. Department of Justice. March 2023. [\[Bureau of Justice\]](#) -
10. Maruschak LM. HIV in Prisons, 2001-2010. Bureau of Justice Statistics: Office of Justice Programs, U.S. Department of Justice. September 13, 2012. [\[Bureau of Justice\]](#) -
11. Maruschak LM. HIV in Prisons, 2020—Statistical Tables. Bureau of Justice Statistics: Office of Justice Programs, U.S. Department of Justice. May 2022. [\[Bureau of Justice\]](#) -
12. Centers for Disease Control and Prevention. Estimated HIV Incidence and Prevalence in the United States, 2014–2018. HIV Surveillance Supplemental Report. 2020;25(No. 1):1-77. Published May 2020. [\[CDC\]](#) -
13. Gough E, Kempf MC, Graham L, Manzanero M, Hook EW, Bartolucci A, Chamot E. HIV and hepatitis B and C incidence rates in US correctional populations and high risk groups: a systematic review and meta-analysis. BMC Public Health. 2010;10:777.

[\[PubMed Abstract\]](#) -

14. Bronson J, Stroop J, Zimmer S, Berzofsky M. Drug use, dependence, and abuse among state prisoners and jail inmates, 2007-2009. Bureau of Justice Statistics Special Report. June 2017 (revised August 10, 2020).  
[\[U.S. Department of Justice\]](#) -
15. Meyer JP, Cepeda J, Wu J, Trestman RL, Altice FL, Springer SA. Optimization of human immunodeficiency virus treatment during incarceration: viral suppression at the prison gate. *JAMA Intern Med.* 2014;174:721-9.  
[\[PubMed Abstract\]](#) -
16. Bick JA. Infection control in jails and prisons. *Clin Infect Dis.* 2007;45:1047-55.  
[\[PubMed Abstract\]](#) -
17. Chandler RK, Fletcher BW, Volkow ND. Treating drug abuse and addiction in the criminal justice system: improving public health and safety. *JAMA.* 2009;301:183-90.  
[\[PubMed Abstract\]](#) -
18. Springer SA, Chen S, Altice FL. Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment. *J Urban Health.* 2010;87:592-602.  
[\[PubMed Abstract\]](#) -
19. Springer SA, Qiu J, Saber-Tehrani AS, Altice FL. Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. *PLoS One.* 2012;7:e38335.  
[\[PubMed Abstract\]](#) -
20. Centers for Disease Control and Prevention (CDC). HIV transmission among male inmates in a state prison system—Georgia, 1992-2005. *MMWR Morb Mortal Wkly Rep.* 2006;55:421-6.  
[\[PubMed Abstract\]](#) -
21. Macalino GE, Vlahov D, Sanford-Colby S, Patel S, Sabin K, Salas C, Rich JD. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. *Am J Public Health.* 2004;94:1218-23.  
[\[PubMed Abstract\]](#) -
22. Hammett TM. HIV/AIDS and other infectious diseases among correctional inmates: transmission, burden, and an appropriate response. *Am J Public Health.* 2006;96:974-8.  
[\[PubMed Abstract\]](#) -
23. Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. *MMWR Recomm Rep.* 2018;67:1-31.  
[\[PubMed Abstract\]](#) -
24. Iroh PA, Mayo H, Nijhawan AE. The HIV Care Cascade Before, During, and After Incarceration: A Systematic Review and Data Synthesis. *Am J Public Health.* 2015;105:e5-16.  
[\[PubMed Abstract\]](#) -
25. Tarver BA, Sewell J, Oussayef N. State Laws Governing HIV Testing in Correctional Settings. *J Correct Health Care.* 2016;22:28-40.  
[\[PubMed Abstract\]](#) -

26. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. *MMWR Recomm Rep*. 2006;55:1-17.  
[\[PubMed Abstract\]](#) -
27. Centers for Disease Control and Prevention (CDC). HIV screening of male inmates during prison intake medical evaluation--Washington, 2006-2010. *MMWR Morb Mortal Wkly Rep*. 2011;60:811-3.  
[\[PubMed Abstract\]](#) -
28. Solomon L, Montague BT, Beckwith CG, et al. Survey finds that many prisons and jails have room to improve HIV testing and coordination of postrelease treatment. *Health Aff (Millwood)*. 2014;33:434-42.  
[\[PubMed Abstract\]](#) -
29. Centers for Disease Control and Prevention (CDC). Routine jail-based HIV testing - Rhode Island, 2000-2007. *MMWR Morb Mortal Wkly Rep*. 2010;59:742-5.  
[\[PubMed Abstract\]](#) -
30. Beckwith CG, Zaller ND, Fu JJ, Montague BT, Rich JD. Opportunities to diagnose, treat, and prevent HIV in the criminal justice system. *J Acquir Immune Defic Syndr*. 2010;55 Suppl 1:S49-55.  
[\[PubMed Abstract\]](#) -
31. Westergaard RP, Spaulding AC, Flanigan TP. HIV among persons incarcerated in the USA: a review of evolving concepts in testing, treatment, and linkage to community care. *Curr Opin Infect Dis*. 2013;26:10-6.  
[\[PubMed Abstract\]](#) -
32. Beckwith C, Bazerman L, Gillani F, et al. The feasibility of implementing the HIV seek, test, and treat strategy in jails. *AIDS Patient Care STDS*. 2014;28:183-7.  
[\[PubMed Abstract\]](#) -
33. Beckwith CG, Atunah-Jay S, Cohen J, et al. Feasibility and acceptability of rapid HIV testing in jail. *AIDS Patient Care STDS*. 2007;21:41-7.  
[\[PubMed Abstract\]](#) -
34. de Voux A, Spaulding AC, Beckwith C, et al. Early identification of HIV: empirical support for jail-based screening. *PLoS One*. 2012;7:e37603.  
[\[PubMed Abstract\]](#) -
35. Macgowan R, Margolis A, Richardson-Moore A, et al. Voluntary rapid human immunodeficiency virus (HIV) testing in jails. *Sex Transm Dis*. 2009;36:S9-13.  
[\[PubMed Abstract\]](#) -
36. Seth P, Figueroa A, Wang G, Reid L, Belcher L. HIV Testing, HIV Positivity, and Linkage and Referral Services in Correctional Facilities in the United States, 2009-2013. *Sex Transm Dis*. 2015;42:643-9.  
[\[PubMed Abstract\]](#) -
37. Centers for Disease Control and Prevention. HIV Testing Implementation Guidance for Correctional Settings. January 2009:1-28.  
[\[CDC\]](#) -
38. Roberts TD. Right to treatment for the civilly committed: a new Eighth Amendment basis. *Univ Chic Law Rev*. 1978;45:731-52.  
[\[PubMed Abstract\]](#) -
39. Rosenfeld J. The Origin of Prisoner's Rights: *Estelle v. Gamble* 429 U.S. 97;75-929 (1976).



[\[National Law Review\]](#) -

40. Culbert GJ. Violence and the perceived risks of taking antiretroviral therapy in US jails and prisons. *Int J Prison Health*. 2014;10:94-110.  
[\[PubMed Abstract\]](#) -
41. Merker A, Badowski M, Chiampas T, et al. Effectiveness of Single- and Multiple-Tablet Antiretroviral Regimens in Correctional Setting for Treatment-Experienced HIV Patients. *J Correct Health Care*. 2018;24:52-61.  
[\[PubMed Abstract\]](#) -
42. Wohl DA, Stephenson BL, Golin CE, et al. Adherence to directly observed antiretroviral therapy among human immunodeficiency virus-infected prison inmates. *Clin Infect Dis*. 2003;36:1572-6.  
[\[PubMed Abstract\]](#) -
43. Springer SA, Altice FL. Managing HIV/AIDS in correctional settings. *Curr HIV/AIDS Rep*. 2005;2:165-70.  
[\[PubMed Abstract\]](#) -
44. Altice FL, Mostashari F and Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2001;28:47-58.  
[\[PubMed Abstract\]](#) -
45. Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. *Clin Infect Dis*. 2004;38:1754-60.  
[\[PubMed Abstract\]](#) -
46. Meyer JP, Cepeda J, Taxman FS, Altice FL. Sex-Related Disparities in Criminal Justice and HIV Treatment Outcomes: A Retrospective Cohort Study of HIV-Infected Inmates. *Am J Public Health*. 2015;105:1901-10.  
[\[PubMed Abstract\]](#) -
47. Zaller N, Thurmond P, Rich JD. Limited spending: an analysis of correctional expenditures on antiretrovirals for HIV-infected prisoners. *Public Health Rep*. 2007;122:49-54.  
[\[PubMed Abstract\]](#) -
48. Westergaard RP, Kirk GD, Richesson DR, Galai N, Mehta SH. Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy. *Clin Infect Dis*. 2011;53:725-31.  
[\[PubMed Abstract\]](#) -
49. Costa M, Montague BT, Solomon L, et al. Assessing the Effect of Recent Incarceration in Prison on HIV Care Retention and Viral Suppression in Two States. *J Urban Health*. 2018;95:499-507.  
[\[PubMed Abstract\]](#) -
50. Goldstein MM. Health information privacy in the correctional environment, Oakland, CA: Community Oriented Correctional Health Services. April 2012.  
[\[Community Oriented Correctional Health Services\]](#) -
51. Strick L. Confidentiality and the Incarcerated Patient in the Community Setting. *SGIM FORUM* 2015;38:1-2.  
[\[PubMed Abstract\]](#) -
52. Centers for Disease Control and Prevention (CDC). Drug-susceptible tuberculosis outbreak in a state correctional facility housing HIV-infected inmates--South Carolina, 1999-2000. *MMWR Morb Mortal*

Wkly Rep. 2000;49:1041-4.

[\[PubMed Abstract\]](#) -

53. Mayer KH, Spaulding A, Stephenson B, Macalino G, Ruby W, Clarke JG, Flanigan TP. Human immunodeficiency virus in correctional facilities: a review. Clin Infect Dis. 2002;35:305-12. [\[PubMed Abstract\]](#) -
54. Bai JR, Befus M, Mukherjee DV, Lowy FD, Larson EL. Prevalence and Predictors of Chronic Health Conditions of Inmates Newly Admitted to Maximum Security Prisons. J Correct Health Care. 2015;21:255-64. [\[PubMed Abstract\]](#) -
55. Binswanger IA, Krueger PM, Steiner JF. Prevalence of chronic medical conditions among jail and prison inmates in the USA compared with the general population. J Epidemiol Community Health. 2009;63:912-9. [\[PubMed Abstract\]](#) -
56. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27-34. [\[PubMed Abstract\]](#) -
57. Hennessey KA, Kim AA, Griffin V, Collins NT, Weinbaum CM, Sabin K. Prevalence of infection with hepatitis B and C viruses and co-infection with HIV in three jails: a case for viral hepatitis prevention in jails in the United States. J Urban Health. 2009;86:93-105. [\[PubMed Abstract\]](#) -
58. Solomon L, Flynn C, Muck K, Vertefeuille J. Prevalence of HIV, syphilis, hepatitis B, and hepatitis C among entrants to Maryland correctional facilities. J Urban Health. 2004;81:25-37. [\[PubMed Abstract\]](#) -
59. Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58:721-8. [\[PubMed Abstract\]](#) -
60. Orlando M, Burnam MA, Beckman R, et al. Re-estimating the prevalence of psychiatric disorders in a nationally representative sample of persons receiving care for HIV: results from the HIV Cost and Services Utilization Study. Int J Methods Psychiatr Res. 2002;11:75-82. [\[PubMed Abstract\]](#) -
61. James DJ, Glaze LE. Mental Health Problems of Prison and Jail Inmates. Bureau of Justice Statistics Special Report. December 14, 2006. [\[U.S. Department of Justice\]](#) -
62. HIV/AIDS Bureau, Special Projects of National Significance Program. Training manual: creating a jail linkage program. Rockville, MD: U.S. Department of Health and Human Services, Health Resources and Services Administration; September, 2013. [\[HRSA\]](#) -
63. WriteExpress Corporation. Begin to Read. Literacy Statistics. [\[Begin to Read\]](#) -
64. Young JD, Patel M, Badowski M, et al. Improved virologic suppression with HIV subspecialty care in a large prison system using telemedicine: an observational study with historical controls. Clin Infect Dis.

2014;59:123-6.

[\[PubMed Abstract\]](#) -

65. Young JD, Patel M. HIV Subspecialty Care in Correctional Facilities Using Telemedicine. *J Correct Health Care*. 2015;21:177-85.  
[\[PubMed Abstract\]](#) -
66. Stephenson BL, Wohl DA, Golin CE, Tien HC, Stewart P, Kaplan AH. Effect of release from prison and re-incarceration on the viral loads of HIV-infected individuals. *Public Health Rep*. 2005;120:84-8.  
[\[PubMed Abstract\]](#) -
67. Fasula AM, Fogel CI, Gelaude D, Carry M, Gaiter J, Parker S. Project power: Adapting an evidence-based HIV/STI prevention intervention for incarcerated women. *AIDS Educ Prev*. 2013;25:203-15.  
[\[PubMed Abstract\]](#) -
68. Springer SA, Spaulding AC, Meyer JP, Altice FL. Public health implications for adequate transitional care for HIV-infected prisoners: five essential components. *Clin Infect Dis*. 2011;53:469-79.  
[\[PubMed Abstract\]](#) -
69. Grinstead O, Zack B, Faigles B. Reducing post-release risk behavior among HIV seropositive prison inmates: the health promotion program. *AIDS Educ Prev*. 2001;13:109-19.  
[\[PubMed Abstract\]](#) -
70. Stephenson BL, Wohl DA, McKaig R, et al. Sexual behaviours of HIV-seropositive men and women following release from prison. *Int J STD AIDS*. 2006;17:103-8.  
[\[PubMed Abstract\]](#) -
71. Adimora AA, Schoenbach VJ. Social context, sexual networks, and racial disparities in rates of sexually transmitted infections. *J Infect Dis*. 2005;191 Suppl 1:S115-22.  
[\[PubMed Abstract\]](#) -
72. Adimora AA, Schoenbach VJ, Doherty IA. HIV and African Americans in the southern United States: sexual networks and social context. *Sex Transm Dis*. 2006;33:S39-45.  
[\[PubMed Abstract\]](#) -
73. Khan MR, Behrend L, Adimora AA, Weir SS, White BL, Wohl DA. Dissolution of primary intimate relationships during incarceration and implications for post-release HIV transmission. *J Urban Health*. 2011;88:365-75.  
[\[PubMed Abstract\]](#) -
74. Larney S, Hado S, McKenzie M, Rich JD. Unknown quantities: HIV, viral hepatitis, and sexually transmitted infections in community corrections. *Sex Transm Dis*. 2014;41:283.  
[\[PubMed Abstract\]](#) -
75. Cropsey KL, Binswanger IA, Clark CB, Taxman FS. The unmet medical needs of correctional populations in the United States. *J Natl Med Assoc*. 2012;104:487-92.  
[\[PubMed Abstract\]](#) -

## References

- Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. *Clin Infect Dis*. 2007;45:770-8.

[\[PubMed Abstract\]](#) -

- Baillargeon J, Giordano TP, Rich JD, Wu ZH, Wells K, Pollock BH, Paar DP. Accessing antiretroviral therapy following release from prison. *JAMA*. 2009;301:848-57.  
[\[PubMed Abstract\]](#) -
- Baillargeon JG, Giordano TP, Harzke AJ, Baillargeon G, Rich JD, Paar DP. Enrollment in outpatient care among newly released prison inmates with HIV infection. *Public Health Rep*. 2010;125 Suppl 1:64-71.  
[\[PubMed Abstract\]](#) -
- Binswanger IA, Merrill JO, Krueger PM, White MC, Booth RE, Elmore JG. Gender differences in chronic medical, psychiatric, and substance-dependence disorders among jail inmates. *Am J Public Health*. 2009;100:476-82.  
[\[PubMed Abstract\]](#) -
- Centers for Disease Control and Prevention (CDC). HIV screening of male inmates during prison intake medical evaluation—Washington, 2006-2010. *MMWR Morb Mortal Wkly Rep*. 2011;60:811-3.  
[\[PubMed Abstract\]](#) -
- Dean-Gaitor HD, Fleming PL. Epidemiology of AIDS in incarcerated persons in the United States, 1994-1996. *AIDS*. 1999;13:2429-35.  
[\[PubMed Abstract\]](#) -
- El-Sadr WM, Lundgren J, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. *N Engl J Med*. 2006;355:2283-96.  
[\[PubMed Abstract\]](#) -
- Flanigan TP, Zaller N, Beckwith CG, et al. Testing for HIV, sexually transmitted infections, and viral hepatitis in jails: still a missed opportunity for public health and HIV prevention. *J Acquir Immune Defic Syndr*. 2010;55 Suppl 2:S78-83.  
[\[PubMed Abstract\]](#) -
- Fogel CI, Belyea M. The lives of incarcerated women: violence, substance abuse, and at risk for HIV. *J Assoc Nurses AIDS Care*. 1999;10:66-74.  
[\[PubMed Abstract\]](#) -
- Ghandnoosh N. Race and Punishment: Racial Perceptions of Crime and Support for Punitive Policies. *The Sentencing Project*. September 2014:1-44.  
[\[The Sentencing Project\]](#) -
- Grinstead OA, Faigles B, Comfort M, et al. HIV, STD, and hepatitis risk to primary female partners of men being released from prison. *Women Health*. 2005;41:63-80.  
[\[PubMed Abstract\]](#) -
- Hall HI, Frazier EL, Rhodes P, et al. Differences in human immunodeficiency virus care and treatment among subpopulations in the United States. *JAMA Intern Med*. 2013;173:1337-44.  
[\[PubMed Abstract\]](#) -
- Hart JE, Jeon CY, Ivers LC, et al. Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review. *J Acquir Immune Defic Syndr*. 2010;54:167-79.  
[\[PubMed Abstract\]](#) -
- Kaeble D, Cowhig M. *Correctional Populations in the United States, 2016*. Bureau of Justice Statistics:

Office of Justice Programs, U.S. Department of Justice. April 29, 2018.

[\[Bureau of Justice Statistics\]](#) -


- Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. *J Acquir Immune Defic Syndr.* 2005;39:446-53.  
[\[PubMed Abstract\]](#) -
- Milloy MJ, Kerr T, Buxton J, et al. Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. *J Infect Dis.* 2011;203:1215-21.  
[\[PubMed Abstract\]](#) -
- Minton TD, Zeng Z. Jail inmates at midyear 2014. Bureau of Justice Statistics: Office of Justice Programs, U.S. Department of Justice. June 11, 2015.  
[\[Bureau of Justice\]](#) -
- Reisner SL, Bailey Z, Sevelius J. Racial/ethnic disparities in history of incarceration, experiences of victimization, and associated health indicators among transgender women in the U.S. *Women Health.* 2014;54:750-67.  
[\[PubMed Abstract\]](#) -
- Stein MS, Spaulding AC, Cunningham M, et al. HIV-positive and in jail: race, risk factors, and prior access to care. *AIDS Behav.* 2013;17 Suppl 2:S108-17.  
[\[PubMed Abstract\]](#) -
- United States Census Bureau. Quick facts—United States.  
[\[United States Census Bureau\]](#) -

# Figures

**Figure 1 Persons Incarcerated in Prisons or Jails Over Time**


On any given day in the United States, there are significantly more individuals incarcerated in prisons than in jails, but many more persons move through jails over time than in prisons. The higher total annual volume in a jail is due to much higher admission and release rates than in prisons, where incarcerated persons typically have long sentences.

Illustration: David H. Spach, MD



**Figure 2 Global Prison Population Totals, by Country, 2021**


Source: World Prison Brief: Highest to Lowest—Prison Population Total. World Prison Brief, Institute for Criminal Policy Research. 2021.



**Figure 3 Estimated Number of Incarcerated Adults in United States, 1980 through 2021**

The numbers for each year represent a sample taken at one point in time. Persons who are incarcerated represent persons in prison (federal prison or state) and in local jails.

Source: Carson EA, Klucklow R. Correctional Populations in the United States, 2021 – Statistical Tables. Bureau of Justice Statistics: Office of Justice Programs, U.S. Department of Justice. February, 2023.






**Figure 4 Persons with HIV (and HIV Rate) per 100,000 in State and Federal Prisons Combined, 1991-2021**

The numbers for each year represent a sample taken at one point in time and represent persons with diagnosed HIV.

Source: Maruschak LM. Statistical Tables. Bureau of Justice Statistics: Office of Justice Programs, U.S. Department of Justice.



**Figure 5 HIV Testing Practices During the Prison Intake Process, 2011, 2015, and 2021**


Source: Maruschak LM, Bronson J. HIV in Prisons, 2015—Statistical Tables. Bureau of Justice Statistics: Office of Justice Programs, U.S. Department of Justice. August 24, 2017. Maruschak LM, Bronson J. HIV in Prisons, 2021—Statistical Tables. Bureau of Justice Statistics: Office of Justice Programs, U.S. Department of Justice. March 2023.

HIV Testing Practices During Prison Intake Process, 2011, 2015, 2021			
Intake HIV Practice	Year		
	2011	2015	2021
Mandatory	14	15	16
Opt-Out	13	17	23
Opt-In	10	8	7
Upon Assessment	2	3	3
Did Not Report	3	2	1

**Figure 6 CDC-Funded HIV Testing in Correctional Facilities and Percentage HIV Positive, United States, 2009-2013**

These data are from correctional facilities in 59 CDC-funded Health Department jurisdictions.


Source: Seth P, Figueroa A, Wang G, Reid L, Belcher L. HIV Testing, HIV Positivity, and Linkage and Referral Services in Correctional Facilities in the United States, 2009-2013. Sex Transm Dis. 2015;42:643-9.



### Figure 7 The HIV Care Cascade Before, During, and After Incarceration


This graphic represents systematic review and data synthesis compiled up to January 13, 2015. For this analysis, undetectable HIV RNA was defined as HIV RNA level of less than 500 copies/mL.

Source: Iroh PA, Mayo H, Nijhawan AE. The HIV Care Cascade Before, During, and After Incarceration: A Systematic Review and Data Synthesis. Am J Public Health. 2015;105:e5-16.



**Figure 8 Number of AIDS-Related Deaths Among Persons in State Prisons, 1991-2019**


Source: Maruschak LM. HIV in Prisons, 2020—Statistical Tables. Bureau of Justice Statistics: Office of Justice Programs, U.S. Department of Justice. May 2022.



**Figure 9 Estimated Number of Persons Supervised by United States Adult Correctional Systems, by Correctional Status, 2021**

\*The total number for community supervision is adjusted to exclude persons on parole who were also on probation.

Source: Carson EA, Klucklow R. Correctional Populations in the United States, 2021 - Statistical Tables. Bureau of Justice Statistics: Office of Justice Programs, U.S. Department of Justice. February, 2023.



<p><b>Table 1. CDC HIV Testing Implementation Guidance for Correctional Setting</b></p> <p><b>Linkage to Services for Inmates Newly Diagnosed with HIV: Immediate Clinical Management Issues</b></p>
<ul style="list-style-type: none"> <li>• HIV prevention counseling.</li> </ul>
<ul style="list-style-type: none"> <li>• Referral for mental health support as indicated.</li> </ul>
<ul style="list-style-type: none"> <li>• Medical evaluation including staging of HIV and diagnosis of comorbidities and opportunistic infections.</li> </ul>
<ul style="list-style-type: none"> <li>• Referral to an HIV provider or specialist depending on the HIV medical provider’s experience, the stage of HIV, and complexity of medical issues.</li> </ul>
<ul style="list-style-type: none"> <li>• Expedited HIV care may be necessary for special clinical circumstances including acute HIV, an acute opportunistic infection, and HIV during pregnancy.</li> </ul>

Source:

- Centers for Disease Control and Prevention. HIV Testing Implementation Guidance for Correctional Settings. January 2009:1-28. [[CDC](#)]

Table 2. <b>CDC HIV Testing Implementation Guidance for Correctional Setting</b>	
<b>Linkage to Appropriate Medical Care Upon Release from Custody</b>	
	<ul style="list-style-type: none"> <li>• Develop a list of medical providers in the community to which the inmates will be returning. Many states have resource manuals listing HIV care providers.</li> </ul>
	<ul style="list-style-type: none"> <li>• Contact your local or state health department for assistance with locating providers who are willing to accept uninsured persons.</li> </ul>
	<ul style="list-style-type: none"> <li>• Most inmates with HIV will qualify for free or low-cost medical treatment at clinics federally funded through the Ryan White HIV/AIDS Treatment Modernization Act of 2006.</li> </ul>
	<ul style="list-style-type: none"> <li>• Assist the inmate with scheduling an appointment with the community care provider. If possible, allow the community care provider to visit the inmate before release. Research has shown that face-to-face contact before release results in increased likelihood of continuity in the community. Having the inmate talk to a provider, a nurse, or a counselor at the follow-up clinic may help with concrete linkage to services. If appointments cannot be made in advance, make walk-in arrangements with clinical providers.</li> </ul>
	<ul style="list-style-type: none"> <li>• Provide the inmate with date, time, and location of first post-release appointment in writing. Stress to inmates the importance of attending their first scheduled appointment in the community, and the appointment should be as early as possible after release.</li> </ul>
	<ul style="list-style-type: none"> <li>• Provide the inmate with a copy of the relevant medical record or clinical summary free of charge. Alternatively, send information to the community provider after obtaining written consent for release of information from the inmate.</li> </ul>
	<ul style="list-style-type: none"> <li>• Collaborate with state and local offices administering benefit and entitlement programs to facilitate pre-release applications and benefit reinstatements. Some correctional systems have arranged partnerships to allow processing of Social Security Administration (SSA) and Medicare applications before release, as recommended by the SSA and the Centers for Medicare and Medical Services.</li> </ul>
	<ul style="list-style-type: none"> <li>• Complete applications for medical services in conjunction with the inmate.</li> </ul>

Source:

- Centers for Disease Control and Prevention. HIV Testing Implementation Guidance for Correctional Settings. January 2009:1-28. [[CDC](#)]



